Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)

What changed: Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)

Every dated change on the records linked to Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone3This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordVaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Facts on this page last checked
When this page itself was last checked or edited.

2011 · 1

2011MilestoneVaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Long-term follow-up of the DES cohort confirms continued excess of clear cell adenocarcinoma and other harms
A milestone in how this cancer is treated.

1992 · 1

1992MilestoneVaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Registry data define the lifetime risk in DES-exposed daughters at about one in a thousand
A milestone in how this cancer is treated.

1971 · 1

1971MilestoneVaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Herbst links vaginal clear cell adenocarcinoma in young women to prenatal DES exposure; the FDA advises against DES in pregnancy
A milestone in how this cancer is treated.